Affinia Therapeutics is honored to have our CEO, Rick Modi as a featured guest on the #BusinessofBiotech podcast with Matthew Pillar that was taped during #JPM25. Rick shares how his upbringing shaped his leadership style, his journey from pharma to biotech, and the groundbreaking #genetherapy work Affinia is advancing. “There’s no pay for a few months. But there’s the hope, the conviction, and the courage to say wow we could do something here,” said Rick. ? In the podcast, Rick talks about AFTX-201 for #BAG3 dilated cardiomyopathy (#DCM). BAG3 DCM is one of 6,000+ #rarediseases affecting 300 million people worldwide that greatly impairs both quality of life and survival. A potential best-in-class gene therapy given as a simple one-time IV injection, AFTX-201 is currently undergoing IND-enabling studies. Affinia completed a successful pre-IND meeting with the FDA in late 2024 and plans to file an IND in the fourth quarter of 2025. Affinia Therapeutics works relentlessly with high quality and high integrity to discover and develop transformative #geneticmedicines, starting with diseases of the heart, like BAG3DCM, and of the nervous system, that will have a lasting and positive impact on the lives of those affected by devastating diseases. #rationallydesignedcapsids ? Tune in to the full discussion here: https://bit.ly/3DwdRuG
Affinia Therapeutics
生物技术研究
Waltham，Massachusetts 9,771 位关注者
Building the next generation of gene therapies
关于我们
We are a team with decades of proven success in translating science from bench to bedside across many companies and medicines, in gene therapy and beyond. We are driven by a purpose: to make a lasting positive impact in the lives of people affected by devastating rare and prevalent diseases where the genetic cause is understood. Our thesis is simple and our vision, clear: gene therapies have an immense potential to cure many diseases with a one-time dose, but they are limited by current delivery methods for the genetic payload. We formed Affinia Therapeutics to singularly focus on creating innovations that can expand the reach of gene therapies to more prevalent diseases. We're re-engineering adeno-associated virus serotype 9 (AAV9), a gene therapy delivery method that has shown promise but only in a small number of diseases. Our initial focus is on diseases of the heart and the nervous system, where we foresee a generational change in the treatment paradigm similar to what has happened in the treatment of cancers. This is because advances in science are identifying new genes associated with diseases of the heart and the nervous system, making a compelling case for genetic medicines. The heart and nervous system are also tissues where targeted delivery of the therapeutic genetic payload is currently inadequate. Our ART platform gives us an advantage to develop first-in-class or best-in-class product candidates. As an early team member you will play a key role in setting our culture and values. You will be working alongside the founding management team who have a track record of success in the industry. The pace of work is dynamic, fast and fun. Our site includes: State of the Art lab space & Equipment- Healthy Cafe, Outdoor Patio, State of the Art Gym/Yoga Studio, Lounge ( Pool Table/ Golf Simulator ), Free/Plentiful Parking and More! Join Us!
- 网站
-
https://www.affiniatx.com
Affinia Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Waltham，Massachusetts
- 类型
- 私人持股
- 创立
- 2019
- 领域
- gene therapy、rare diseases、AAV、vector、capsid、research、biotechnology、Teamwork、Integrity、Passion和discovery
地点
-
主要
获取路线
43 Foundry
Ste 120
US，Massachusetts，Waltham，02453
Affinia Therapeutics员工
动态
-
Today is #RareDiseaseDay. #BAG3 dilated cardiomyopathy (#DCM) is one of 6,000+ #rarediseases affecting 300 million people worldwide. BAG3 DCM is a disease that greatly impairs both quality of life and survival. Affinia Therapeutics works relentlessly with high quality and high integrity to discover and develop transformative #geneticmedicines, starting with diseases of the heart, like BAG3 DCM, and of the nervous system, that will have a lasting and positive impact on the lives of those affected by devastating diseases. #rationallydesignedcapsids
-
-
Today is #RareDiseaseDay. #BAG3 dilated cardiomyopathy (#DCM) is one of 6,000+ #rarediseases affecting 300 million people worldwide. BAG3 DCM is a disease that greatly impairs both quality of life and survival. Affinia Therapeutics works relentlessly with high quality and high integrity to discover and develop transformative #geneticmedicines, starting with diseases of the heart, like BAG3 DCM, and of the nervous system, that will have a lasting and positive impact on the lives of those affected by devastating diseases. #rationallydesignedcapsids
-
-
Today is #RareDiseaseDay. #BAG3 dilated cardiomyopathy (#DCM) is one of 6,000+ #rarediseases affecting 300 million people worldwide. BAG3 DCM is a disease that greatly impairs both quality of life and survival. Affinia Therapeutics works relentlessly with high quality and high integrity to discover and develop transformative #geneticmedicines, starting with diseases of the heart, like BAG3 DCM, and of the nervous system, that will have a lasting and positive impact on the lives of those affected by devastating diseases. #rationallydesignedcapsids
-
-
Affinia Therapeutics is excited to announce the appointment of Hideo Makimura, MD, PhD as its Chief Medical Officer. Hideo is a seasoned physician-scientist and biopharmaceutical R&D executive with significant early- and late-stage drug development experience across multiple therapeutic areas including cardiovascular and neuroscience diseases. He has taken many novel molecules into humans for the first time and has contributed to more than 12 successful IND, CTA, and regulatory approval submissions. #genetherapy #rationallydesignedcapsids https://bit.ly/4hBo8EA
-
Affinia Therapeutics is delighted to announce the nomination of AFTX-201 as the company’s development candidate for the treatment of #BAG3 dilated cardiomyopathy (DCM). “BAG3 DCM is a disease that greatly impairs both quality of life and survival. Although conventional treatments including guideline-directed medical therapies, cardiac resynchronization therapy, and implanted defibrillators can be used in patients with BAG3 DCM, there is no specific disease-modifying treatment available and patients still may progress to heart failure, die prematurely, or require advanced therapies like heart transplantation,” said Barry Greenberg, M.D., an internationally recognized pioneer in the field of heart failure and Director of the Advanced Heart Failure Treatment Program at University of California San Diego Health. “Development of AFTX-201 as a one-time therapy that addresses the genetic root cause of BAG3 DCM could be transformative.” A potential best-in-class gene therapy given as a simple one-time IV injection, AFTX-201 is currently undergoing #IND-enabling studies. Affinia completed a successful pre-IND meeting with the #FDA in late 2024 and plans to file an IND in the fourth quarter of 2025. ?#rationallydesignedcapsids https://bit.ly/40cYpuG
-
Affinia Therapeutics is delighted to announce the nomination of AFTX-201 as the company’s development candidate for the treatment of #BAG3 dilated cardiomyopathy (DCM). “BAG3 DCM is a disease that greatly impairs both quality of life and survival. Although conventional treatments including guideline-directed medical therapies, cardiac resynchronization therapy, and implanted defibrillators can be used in patients with BAG3 DCM, there is no specific disease-modifying treatment available and patients still may progress to heart failure, die prematurely, or require advanced therapies like heart transplantation,” said Barry Greenberg, M.D., an internationally recognized pioneer in the field of heart failure and Director of the Advanced Heart Failure Treatment Program at University of California San Diego Health. “Development of AFTX-201 as a one-time therapy that addresses the genetic root cause of BAG3 DCM could be transformative.” A potential best-in-class gene therapy given as a simple one-time IV injection, AFTX-201 is currently undergoing #IND-enabling studies. Affinia completed a successful pre-IND meeting with the #FDA in late 2024 and plans to file an IND in the fourth quarter of 2025. ?#rationallydesignedcapsids https://bit.ly/40cYpuG
-
Affinia Therapeutics was thrilled to have students from Brandeis University visit our offices to learn about #genetherapy innovations and the work we are doing to help advance #rationallydesigned gene therapies for devastating cardiovascular and neurological diseases. Sincerest thanks to Jason Leturmy and the Brandeis University — Hiatt Career Center External Engagement team for coordinating this inspiring visit. #rationallydesignedcapsids
?? At our employer visit to Affinia Therapeutics headquarters in Waltham, MA, students received an insider’s perspective on gene therapy innovations — all minutes from Brandeis campus! ?? Our sincere thanks to the Affinia Therapeutics team for a welcoming and informative visit! Darren Ottaviani - Senior Director, Human Resources; John Reece-Hoyes - Senior Director, Head of Vector Biology; Matt Edwards - Senior Director, Head of Process Science; Cynthia Pryce - Principal Scientist; May Ribeiro, PhD - Preclinical Analytics Scientist II; and Erin Noll - Executive Assistant & Office Manager. ?? Shout-out to Jason Leturmy and the Hiatt External Engagement team for coordinating this career exploration opportunity for Brandeis students! #careercenter #careerexploration #affiniatherapeutics #brandeis
-
-
Affinia Presents! Affinia participated at the Advanced Therapies USA 2024 Conference held last week. Michael DiBiasio-White, Ph.D, head of process development and manufacturing innovations-associate director (left photo) delivered a presentation entitled, “Pulling the right lever: AAV proprietary plasmid designs, production media and transfection reagent screenings improve manufacturability for novel and WT capsids,” and Matt Edwards, senior director, head of process science (right photo, far left) participated in a panel discussion, “Streamlining Process Development.” The Advanced Therapies conference serves as a pivotal gathering for industry leaders, researchers, and innovators, offering deep insights into the latest advancements and regulatory landscapes shaping advanced therapies including cell and gene therapies, gene editing, stem cells, and regenerative medicine. #rationallydesignedcapsids #genetherapy https://bit.ly/3CD8UQ9
-
-
Affinia Therapeutics is thrilled to have our CEO Rick Modi interviewed for a feature, “How #rationallydesigned therapeutics can revolutionize #genetherapy,” that appears in Vital Signs, produced by Onyx and published in Fortune magazine on December 1. Rick talks about how Affinia is working to solve the one of the challenges of gene therapy - delivery. You can read Rick’s interview here: https://bit.ly/3CIkYPQ #rationallydesignedcapsids